## **Core Concept**
The diagnosis of insulinoma, a type of pancreatic tumor that produces excess insulin, relies on demonstrating an inappropriate elevation of insulin levels during episodes of hypoglycemia. The gold standard test should accurately assess insulin production and its relationship to blood glucose levels.

## **Why the Correct Answer is Right**
The **72-hour fasting test** is considered the gold standard for diagnosing insulinoma. During this test, patients fast under close supervision, and blood glucose, insulin, and C-peptide levels are monitored. In patients with insulinoma, this test typically reveals hypoglycemia with inappropriately elevated insulin and C-peptide levels, indicating endogenous insulin production despite low blood glucose. This test is diagnostic because it directly assesses the body's ability to regulate blood glucose and insulin levels over an extended period.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While **Fasting blood glucose** can indicate hypoglycemia, a single measurement cannot confirm insulinoma, as it does not assess the relationship between glucose and insulin levels.
- **Option B:** **Oral glucose tolerance test (OGTT)** is not typically used for diagnosing insulinoma. It can actually induce hypoglycemia in some patients with insulinoma but is not the best test for directly measuring insulin production during hypoglycemic episodes.
- **Option C:** **Prolonged glucose monitoring** might be part of the diagnostic process but is not as specific or structured as the 72-hour fasting test for directly diagnosing insulinoma.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that during a **72-hour fasting test**, the presence of **hypoglycemia** (blood glucose 3 μU/mL) and **elevated C-peptide** levels strongly supports the diagnosis of insulinoma. This is because exogenous insulin administration would suppress C-peptide production.

## **Correct Answer:** D. 72-hour fasting test.